Addressing the COVID-19 challenge with computer modeling & simulation

Each day, we wake up hoping for positive news about vaccines and therapies to combat COVID-19. More than 70 candidate molecules are being evaluated for repurposing to treat COVID-19. This number will grow thanks to the use of new combination therapies discovered under an aggressive, disciplined, and quantitative approach to evaluating candidates called model-informed drug development (MIDD)…

Model-based meta-analysis for comparative efficacy and safety of therapeutics for COVID-19

Certara is launching the COVID-19 Clinical Outcomes Database, funded by the COVID-19 Therapeutics Accelerator. The Database includes observational studies and clinical trials with more than 10 patients that evaluate specific treatment options to improve disease outcome. It captures all patient characteristics, safety and efficacy outcomes, biomarkers and viral load data. The database also includes studies (>100 patients) that evaluate patient characteristics stratified by disease outcome such as death, or progression to severe or critical disease and studies (>10 patients) that report the time course of viral load, vital signs, and biomarkers.

Exploring the Effect of COVID-19 on HTA Bodies Now and in the Future

The COVID-19 pandemic has turned our lives upside down and so many questions remain, including around how it is affecting health technology assessment (HTA) bodies. HTA bodies report that they have had to ramp up and are increasingly relying on smaller evidence sets. Going forward the priorities for and speed of assessments, particularly for vaccines, is likely to increase. On top of this, economies struggling with significantly increased levels of debt may respond by tightening budgets outside communicable diseases thus affecting assessment priorities, methods and recommendations.